Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Zeiss Meditec buys Dutch firm for nearly 1 billion euros

Published 15/12/2023, 19:43
© Reuters.

BERLIN (Reuters) - German medical technology firm Carl Zeiss Meditec said on Friday it had bought the Dutch Ophthalmic Research Center, a developer of devices for eye surgery, for nearly 1 billion euros ($1.09 billion).

Carl Zeiss Meditec, a subsidiary of the Zeiss Group which is known for its camera lenses, said the acquisition would further strengthen its position as the fastest growing manufacturer of ophthalmic medical devices globally.

The DORC's products are used by ophthalmic surgeons around the world to treat a wide range of vision-threatening conditions, it said.

Zeiss bought DORC for 985 mln euros, nearly five times the Dutch firm's expected turnover this year of some 200 million euros.

($1 = 0.9181 euro)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.